COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS

被引：0
|
作者：
Olasupo, O. [1 ]
Matino, D. [1 ]
Iorio, A. [1 ]
Blackhouse, G. [1 ]
Xie, F. [1 ]
Tarride, J. E. [1 ]
机构：
[1] McMaster Univ, Hamilton, ON, Canada
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE476
引用
收藏
页码：S428 / S428
页数：1
相关论文
共 50 条
  • [21] Comparing the cost-effectiveness of APCC and rFVIIa prophylaxis regimen in the management of hemophilia patients with inhibitors in the UK
    Oladapo, A.
    Epstein, J.
    Holmes, S.
    HAEMOPHILIA, 2014, 20 : 81 - 81
  • [22] Comparing the cost-effectiveness of aPCC and rFVIIa prophylaxis regimen in the management of hemophilia patients with inhibitors in the US
    Oladapo, Abiola
    Aaron, Novack
    Epstein, Joshua
    HAEMOPHILIA, 2014, 20 : 99 - 99
  • [23] Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    HAEMOPHILIA, 2020, 26 (01) : 41 - 46
  • [24] COST-EFFECTIVENESS ANALYSIS OF TUROCTOCOG ALFA PEGOL IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS IN COLOMBIA
    Moreno-Calderon, A.
    Casas-Ramirez, D.
    Sotomayor, Carrasquilla M.
    Camerano-Ruiz, R.
    Tamara, Moyano L.
    Zakzuk, Alvis N. R.
    Zakzuk, Alvis N. J.
    VALUE IN HEALTH, 2024, 27 (06) : S96 - S96
  • [25] Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
    Kragh, Nana
    Tytula, Anna
    Pochopien, Michal
    Aballea, Samuel
    Toumi, Mondher
    Hakimi, Zalmai
    Nazir, Jameel
    Bystricka, Linda
    Fatoye, Francis
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (03) : 262 - 270
  • [26] COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS IN PORTUGAL
    Soares, V
    Freitas, L. A.
    Cafe, A.
    VALUE IN HEALTH, 2019, 22 : S905 - S905
  • [27] ECONOMIC EVALUATION OF IMMUNE TOLERANCE INDUCTION FOR CHILDREN WITH SEVERE HEMOPHILIA A AND HIGH-RESPONDING INHIBITORS: A COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS WITH EMICIZUMAB
    Camelo, R.
    Barbosa, M. M.
    Araujo, M. S.
    Muniz Junior, R. L.
    Guerra Junior, A. A.
    Godman, B.
    Rezende, S. M.
    Acurcio, F. D. A.
    Martin, A. P.
    Alvares-Teodoro, J.
    HAEMOPHILIA, 2023, 29 : 52 - 52
  • [28] Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab
    Camelo, Ricardo Mesquita
    Barbosa, Mariana Michel
    Araujo, Maiara Silva
    Muniz, Roberto Lucio, Jr.
    Guerra, Augusto Afonso, Jr.
    Godman, Brian
    Rezende, Suely Meireles
    Acurcio, Francisco de Assis
    Martin, Antony P.
    Alvares-Teodoro, Juliana
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 34 : 31 - 39
  • [29] COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
    Souza, P.
    Puopolo, G. R.
    Leme-Souza, R.
    VALUE IN HEALTH, 2019, 22 : S847 - S847
  • [30] Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China
    Liu, Guoqing
    Xin, Qing
    Chen, Zhenping
    Li, Lanting
    Chen, Ting
    Wu, Runhui
    CLINICAL THERAPEUTICS, 2021, 43 (09) : 1536 - 1546
12345